Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of the availability of Ramipril in each strength and formulation; and what steps he is taking to ensure continuity of supply to patients.

All strengths of ramipril capsules and tablets remain available, however, the Department is aware that ramipril 1.25 milligrams capsules are in more limited supply until late July 2026 due to manufacturing issues affecting some suppliers. We are working closely with suppliers to resolve the disruptions as soon as possible. We have issued comprehensive management guidance to the National Health Service to manage affected patients during this time, which includes advice on the use of alternative medicines. We have also issued a Serious Shortage Protocol to limit prescriptions to one month’s supply to support equitable distribution of available stocks.